Ruiz-Herrera Xarubet, de Los Ríos Ericka A, Díaz Juan M, Lerma-Alvarado Ricardo M, Martínez de la Escalera Lucía, López-Barrera Fernando, Lemini María, Arnold Edith, Martínez de la Escalera Gonzalo, Clapp Carmen, Macotela Yazmín
Instituto de Neurobiología (X.R.-H., E.A.d.l.R., L.M.d.l.E., F.L.-B., M.L., E.A., G.M.d.l.E., C.C., Y.M.), Universidad Nacional Autónoma de México (UNAM), Campus UNAM-Juriquilla, 76230 Querétaro, Mexico; and Hospital General de Querétaro (J.M.D., R.M.L.-A.), Servicio de Cirugía General, Servicios de Salud del Estado de Querétaro, 76170 Querétaro, Mexico.
Endocrinology. 2017 Jan 1;158(1):56-68. doi: 10.1210/en.2016-1444.
Excessive accumulation of body fat triggers insulin resistance and features of the metabolic syndrome. Recently, evidence has accumulated that obesity, type 2 diabetes, and metabolic syndrome are associated with reduced levels of serum prolactin (PRL) in humans and rodents, raising the question of whether low PRL levels contribute to metabolic dysfunction. Here, we have addressed this question by investigating the role of PRL in insulin sensitivity and adipose tissue fitness in obese rodents and humans. In diet-induced obese rats, treatment with PRL delivered via osmotic mini-pumps, improved insulin sensitivity, prevented adipocyte hypertrophy, and reduced inflammatory cytokine expression in visceral fat. PRL also induced increased expression of Pparg and Xbp1s in visceral adipose tissue and elevated circulating adiponectin levels. Conversely, PRL receptor null mice challenged with a high-fat diet developed greater insulin resistance, glucose intolerance, and increased adipocyte hypertrophy compared with wild-type mice. In humans, serum PRL values correlated positively with systemic adiponectin levels and were reduced in insulin-resistant patients. Furthermore, PRL circulating levels and PRL produced by adipose tissue correlated directly with the expression of PPARG, ADIPOQ, and GLUT4 in human visceral and sc adipose tissue. Thus, PRL, acting through its cognate receptors, promotes healthy adipose tissue function and systemic insulin sensitivity. Increasing the levels of PRL in the circulation may have therapeutic potential against obesity-induced metabolic diseases.
体内脂肪过度堆积会引发胰岛素抵抗和代谢综合征的特征。最近,越来越多的证据表明,肥胖、2型糖尿病和代谢综合征与人类及啮齿动物血清催乳素(PRL)水平降低有关,这就提出了一个问题,即低PRL水平是否会导致代谢功能障碍。在此,我们通过研究PRL在肥胖啮齿动物和人类胰岛素敏感性及脂肪组织健康中的作用来解决这个问题。在饮食诱导的肥胖大鼠中,通过渗透微型泵给予PRL进行治疗,可改善胰岛素敏感性,防止脂肪细胞肥大,并降低内脏脂肪中炎性细胞因子的表达。PRL还可诱导内脏脂肪组织中Pparg和Xbp1s的表达增加,并提高循环脂联素水平。相反,与野生型小鼠相比,高脂饮食喂养的PRL受体缺失小鼠出现了更严重的胰岛素抵抗、葡萄糖不耐受和脂肪细胞肥大增加。在人类中,血清PRL值与全身脂联素水平呈正相关,且在胰岛素抵抗患者中降低。此外,循环PRL水平和脂肪组织产生的PRL与人类内脏和皮下脂肪组织中PPARG、ADIPOQ和GLUT4的表达直接相关。因此,PRL通过其同源受体发挥作用,促进健康的脂肪组织功能和全身胰岛素敏感性。提高循环中PRL的水平可能对肥胖诱导的代谢性疾病具有治疗潜力。